Cited by 337Wnt/β-catenin signaling in development and cancerSignaling Pathways in DiseaseColorectal Cancer Treatments and Studies

An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/ wingless signaling pathway

Open access
Gonsalves, Foster C., Klein, Keren, Carson, Brittany B., Katz, Shauna, Ekas, Laura A., Evans, Steve, Nagourney, Robert, Cardozo, Timothy +2 more·2011·Proceedings of the National Academy of Sciences

Abstract

Misregulated β-catenin responsive transcription (CRT) has been implicated in the genesis of various malignancies, including colorectal carcinomas, and it is a key therapeutic target in combating various cancers. Despite significant effort, successful clinical implementation of CRT inhibitory therapeutics remains a challenging goal. This is, in part, because of the challenge of identifying inhibitory compounds that specifically modulate the nuclear transcriptional activity of β-catenin while not affecting its cytoskeletal function in stabilizing adherens junctions at the cell membrane. Here, we report an RNAi-based modifier screening strategy for the identification of CRT inhibitors. Our data provide support for the specificity of these inhibitory compounds in antagonizing the transcriptional function of nuclear β-catenin. We show that these inhibitors efficiently block Wnt/β-catenin–induced target genes and phenotypes in various mammalian and cancer cell lines. Importantly, these Wnt inhibitors are specifically cytotoxic to human colon tumor biopsy cultures as well as colon cancer cell lines that exhibit deregulated Wnt signaling.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1017496108

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several compounds have been selected as inhibitors targeting β-catenin PPI, including small molecules such as ICG-001, NLs-StAx-h, and CRT inhibitors (iCRT3, iCRT5, iCRT14), Henryin, PKF115-584 and CGP049090.

    “In addition, several compounds have been selected as inhibitors targeting β-cateninde PPI, including small molecules such as ICG-001 (176),448 NLs-StAx-h (177)449 and CRT inhibitors (iCRT3 (178), iCRT5 (179), iCRT14 (180)),450 Henryin (181),451 PKF115-584 (182) and CGP049090 (183).452”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gonsalves, F. C., Klein, K., Carson, B. B., Katz, S., Ekas, L. A., Evans, S., Nagourney, R., Cardozo, T., Brown, A. M. C., & DasGupta, R.
Affiliations
  • NYU Langone Health (US)
  • Department of Pharmacology and
  • Weill Cornell Medicine (US)
  • Rational Therapeutics, Long Beach, CA 90806
Venue
Proceedings of the National Academy of Sciences
Published
2011-03-10
Volume
108
Issue
15
Pages
5954-5963
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2146839729
Cited by
337
References
66
Citations by year
2026: 7 · 2025: 19 · 2024: 18 · 2023: 20 · 2022: 20 · 2021: 34 · 2020: 28 · 2019: 19 · 2018: 22 · 2017: 24 · 2016: 21 · 2015: 27 · 2014: 32 · 2013: 22 · 2012: 17
FWCI
10.25
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense (W81XWH)
  • York University
  • National Institutes of Health (W81XWH, 1DP2OD002867-01)
  • National Cancer Institute (R01CA155125, R01CA123238)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R21HD057525)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
Wnt/β-catenin signaling, β-catenin transcriptional activity, small molecule inhibitors, chemical genetic screen, colorectal cancer, colon cancer cell lines, Wnt target genes, cytotoxicity, adherens junctions
MeSH terms
Animals, Antineoplastic Agents, Colonic Neoplasms, Drosophila melanogaster, Drug Screening Assays, Antitumor, Humans, Oxazoles, Transcription, Genetic, Genes, Reporter, Xenograft Model Antitumor Assays, Drosophila Proteins, RNA Interference, Cell Line, Tumor, Wnt Proteins, Wnt1 Protein, beta Catenin, Mice, Small Molecule Libraries, Drug Discovery, High-Throughput Screening Assays

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review